ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

NVLN Novelion Therapeutics Inc

0.68
0.00 (0.00%)
Pre Market
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Novelion Therapeutics Inc NASDAQ:NVLN NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 0.68 0.63 0.6677 0 01:00:00

Current Report Filing (8-k)

11/04/2016 11:02am

Edgar (US Regulatory)


 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 8-K

 


 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of Earliest Event Reported): April 5, 2016

 


 

QLT Inc.

(Exact Name of Registrant as specified in its charter)

 


 

British Columbia, Canada

 

000-17082

 

N/A

(State or Other Jurisdiction
of Incorporation)

 

(Commission
File Number)

 

(IRS Employer
Identification No.)

 

887 Great Northern Way, Suite 250, Vancouver, B.C.

Canada, V5T 4T5

(Address of principal executive offices)

 

Registrant’s telephone number, including area code: (604) 707-7000

 

Not Applicable

(Registrant’s name or former address, if change since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see General Instruction A.2. below):

 

o             Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o             Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o             Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o             Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 1.01.  Entry into a Material Definitive Agreement.

 

On April 7, 2016, QLT Inc. (“ QLT ”) entered into a third amendment (the “ Third Amendment ”) to the employment agreement between QLT and Dr. Geoffrey Cox, dated October 24, 2014 as previously amended April 21, 2015 and October 8, 2015 (the “ Employment Agreement ”), to change the term of Dr. Cox’s employment as Interim Chief Executive Officer of QLT from 18 months from the Commencement Date (as defined in the Employment Agreement) to 24 months from the Commencement Date, expiring on October 22, 2016.  No other changes were made to the terms of the Employment Agreement. A copy of the Third Amendment is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

 

Item 2.01.  Completion of Acquisition or Disposition of Assets.

 

On April 5, 2016, QLT completed the distribution to its shareholders of (i) 4,799,619  common shares of Aralez Pharmaceuticals Inc. (the “ Share Distribution ”) and (ii) US$15,000,000 (together with the Share Distribution, the “ Aralez Distribution ”).  The Aralez Distribution was effected by way of a reorganization of QLT’s share capital pursuant to a statutory plan of arrangement under Section 288 of the Business Corporations Act (British Columbia), which, as previously disclosed, was approved by the QLT shareholders at a special meeting held on March 18, 2016.

 

Item 5.02.  Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

The information provided under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

 

Item 9.01. Financial Statements and Exhibits.

 

(d)               Exhibits

 

Number

 

Description

 

 

 

10.1

 

Third Amendment to Employment Agreement between QLT Inc. and Dr. Geoffrey Cox, dated April 7, 2015

 

2



 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

QLT INC.

 

 

 

By:

/s/ Glen Ibbott

 

Name:

Glen Ibbott

 

Title:

Senior Vice President, Finance and
Chief Financial Officer

 

 

 

Date: April 8, 2016

 

 

3


1 Year Novelion Therapeutics Chart

1 Year Novelion Therapeutics Chart

1 Month Novelion Therapeutics Chart

1 Month Novelion Therapeutics Chart

Your Recent History

Delayed Upgrade Clock